首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   54983篇
  免费   4862篇
  国内免费   2023篇
耳鼻咽喉   263篇
儿科学   2451篇
妇产科学   274篇
基础医学   3147篇
口腔科学   350篇
临床医学   8665篇
内科学   12316篇
皮肤病学   358篇
神经病学   1751篇
特种医学   1631篇
外国民族医学   6篇
外科学   5072篇
综合类   10601篇
现状与发展   13篇
一般理论   1篇
预防医学   2814篇
眼科学   603篇
药学   5622篇
  69篇
中国医学   3058篇
肿瘤学   2803篇
  2024年   140篇
  2023年   1089篇
  2022年   1369篇
  2021年   3071篇
  2020年   2604篇
  2019年   2048篇
  2018年   1910篇
  2017年   1931篇
  2016年   2141篇
  2015年   2043篇
  2014年   3515篇
  2013年   3960篇
  2012年   3210篇
  2011年   3508篇
  2010年   2744篇
  2009年   2506篇
  2008年   2536篇
  2007年   2687篇
  2006年   2422篇
  2005年   2309篇
  2004年   2093篇
  2003年   2004篇
  2002年   1270篇
  2001年   1114篇
  2000年   1022篇
  1999年   775篇
  1998年   702篇
  1997年   663篇
  1996年   604篇
  1995年   512篇
  1994年   432篇
  1993年   312篇
  1992年   302篇
  1991年   240篇
  1990年   194篇
  1989年   210篇
  1988年   191篇
  1987年   144篇
  1986年   145篇
  1985年   243篇
  1984年   168篇
  1983年   132篇
  1982年   135篇
  1981年   122篇
  1980年   89篇
  1979年   86篇
  1978年   55篇
  1977年   44篇
  1976年   45篇
  1975年   31篇
排序方式: 共有10000条查询结果,搜索用时 312 毫秒
51.
52.
目的:观察壮医龙盘止咳方治疗小儿急性支气管炎风热犯肺证的临床疗效。方法:选取60例急性支气管炎风热犯肺证的患儿,将其随机分为2组,每组各30例。治疗组采用壮医龙盘止咳方治疗,对照组予小儿宣肺止咳颗粒治疗,治疗5d后观察2组患儿的疗效、白介素-4(IL-4)和干扰素-γ(INF-γ)含量的变化情况,并进行中医证候评分。结果:总有效率治疗组为89.66%(26/29),对照组为76.67%(23/30),2组比较,差异有统计学意义(P<0.05);治疗组治疗后IL-4高于对照组,INF-γ及中医证候积分均低于对照组,各项指标组间比较,差异均有统计学意义(P<0.05)。结论:壮医龙盘止咳方治疗小儿急性支气管炎风热犯肺证疗效显著,值得推广应用。  相似文献   
53.
54.
目的探讨球囊导管取栓术治疗急性下肢动脉栓塞患者的临床疗效。方法回顾性分析祈福医院2013年1月至2018年12月应用球囊导管微创取栓术治疗的78例急性下肢动脉栓塞患者的临床资料。结果治愈60例,治愈率为89.6%,患肢血供恢复。好转7例(10.4%),肢体缺血症状明显好转。全部患者无截肢。死亡1例(2.6%)。结论球囊导管取栓术是治疗急性动脉栓塞的有效方法,患者一经确诊应尽早手术取栓,有利于提高其保肢率和降低病死率。  相似文献   
55.
56.
57.
58.
Perinatal care providers are likely to encounter adverse events such as intrapartum emergencies, traumatic births, or maternal or fetal deaths. As a result of being directly or indirectly involved in an adverse event, health care providers can be considered second victims. The experience of the second victim phenomenon can lead to significant physical, psychological, and psychosocial sequelae that can negatively impact the provider's personal and professional life for either a short or long duration of time. When health care providers experience an adverse event, they may manifest symptoms of guilt, shame, blame, flashbacks, nightmares, insomnia, isolation, helplessness, and hopelessness, thereby becoming the second victim. Following an adverse event, health care providers who experience second victim phenomenon experience stages of recovery that influence subsequent professional and personal well‐being. Persons who experience the second victim phenomenon can incorporate self‐care behaviors to assist with recovery. Health care organizations have a responsibility to implement efficacious support programs that promote the provider's recovery and a return to safe and full function in the workplace.  相似文献   
59.
Ticagrelor is a cornerstone of modern antithrombotic therapy alongside aspirin in patients with acute coronary syndrome and after percutaneous coronary intervention. Adverse effects such as bleeding and dyspnea have been associated with premature ticagrelor discontinuation, which may limit any potential advantage of ticagrelor over clopidogrel. The randomized trials of ticagrelor captured adverse events, offering the opportunity to more precisely quantify these effects across studies. Therefore, a meta-analysis of 4 randomized clinical trials of ticagrelor conducted between January 2007 and June 2017 was performed to quantify the incidence and causes of premature ticagrelor discontinuation. Among 66,870 patients followed for a median 18 months, premature ticagrelor discontinuation was seen in 25%; bleeding was the most common cause of discontinuation followed by dyspnea. Versus the comparators, the relative risk of dyspnea-related discontinuation during follow-up was 6.4-fold higher, the relative risk of bleeding was 3.2-fold higher, and the relative risk of discontinuation due to any adverse event was 59% higher for patients receiving ticagrelor. Understanding these potential barriers to adherence to ticagrelor is crucial for informed patient-physician decision making and can inform future efforts to improve ticagrelor adherence. This review discusses the incidence, causes, and biological mechanisms of ticagrelor-related adverse effects and offers strategies to improve adherence to ticagrelor.  相似文献   
60.
LC-MS quantification of drug metabolites is sometimes impeded by the availability of internal standards that often requires customized synthesis and/or extensive purification. Although isotopically labeled internal standards are considered ideal for LC-MS/MS based quantification, de novo synthesis using costly isotope-enriched starting materials makes it impractical for early stage of drug discovery. Therefore, quick access to these isotope-enriched compounds without chemical derivatization and purification will greatly facilitate LC-MS/MS based quantification. Herein, we report a novel 18O-labeling technique using metabolizing enzyme carboxylesterase (CES) and its potential application in metabolites quantification study. Substrates of CES typically undergo a two-step oxygen exchange with H218O in the presence of the enzyme, generating singly- and doubly-18O-labeled carboxylic acids; however, unexpected hydrolytic behavior was observed for three of the test compounds – indomethacin, piperacillin and clopidogrel. These unusual observations led to the discovery of several novel hydrolytic mechanisms. Finally, when used as internal standard for LC-MS/MS based quantification, these in situ labeled compounds generated accurate quantitation comparable to the conventional standard curve method. The preliminary results suggest that this method has potential to eliminate laborious chemical synthesis of isotope-labeled internal standards for carboxylic acid-containing compounds, and can be developed to facilitate quantitative analysis in early-stage drug discovery.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号